羟苯磺酸钙联合前列地尔治疗糖尿病肾病的临床疗效分析

目的分析前列地尔联合羟苯磺酸钙治疗糖尿病肾病的临床疗效.方法：将109例糖尿病肾病患者随机分为观察组55例和对照组54例,两组均给予常规治疗,另外观察组加用前列地尔联合羟苯磺酸钙治疗,对照组加用羟苯磺酸钙治疗,观察治疗前后两组24h尿白蛋白排泄率的变化.结果：观察组总有效率为94.55%,明显高于对照组的81.48%（P〈0.O5）;两组24 h尿蛋白排泄率相比,治疗前无统计学差异（P〉0.O5）;治疗后较治疗前两组均显著下降（P〈0.05）;且治疗后观察组低于对照组 （P〈0.O5）.结论：前列地尔联合羟苯磺酸钙治疗糖尿病肾病有很好的的临床疗效,值得临床推广.

ObjectiveTo analysis the clinical effect of treating Diabetic Nephropathy （DN） with Alprostadil and Calcium Dobesilate. Methods： Dividing 109 cases of DN patients into observation group（55 cases） and control group（54 cases） randomly. The control group received routine treatment and Calcium Dobesilate while the observation group received added Alprostadil treatment comparing with control group. Researchers observed the change of the 24h urinary albumin excretion rate（UAER） after receiving treatment. Results：The total effective rate of observation group is 94.55% while the control group is 81.48%, the difference has statistical significance（P〈0.05）; As to 24h UAER, there＇s no statistical significance in both groups before receiving treatment（P〉0.05）, but the 24h UAER of both groups decrease remarkably after receiving treatment（P〈0.05） and the data of observation group is below the control group（P〈0.05）. Conclusion：Treating Diabetic Nephropathy with Alprostadil and Calcium Dobesilate receives a good therapeutic effect, which deserves to be popularized.